Migraine without aura
Drug research and approvals for migraine without aura: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 17 studies of migraine without aura are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 17
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in AdultsNCT07792681 · Phase 2 / Phase 3 · Brise Pharmaceuticals Co., Ltd. · starts Sep 30, 2026
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the…NCT07667621 · Phase 1 · University of South Florida · starts Sep 15, 2026
- Study of EVO756 in Adults With MigraineNCT07616128 · Phase 2 · Evommune, Inc. · starts Jul 29, 2026
- Yogabased Movements for Primary Headaches (Migraine and/or Cluster Headache) - YOURHEADNCT07348783 · Not applicable · Karolinska Institutet · starts May 1, 2026
- New Methods for Evaluating Preventive Migraine TreatmentNCT07071506 · Not applicable · University of Aarhus · starts Jun 19, 2025
- Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients…NCT07022496 · Phase 4 · Ain Shams University · starts Apr 26, 2023
- Substance P-Induced Migraine Attacks Without AuraNCT06959004 · Not applicable · Danish Headache Center · starts May 13, 2025
- Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP QuantificationNCT06674772 · Not reported · Hospital Universitari Vall d'Hebron Research Institute · starts Nov 29, 2022
- Trial Designs for Evaluating Migraine TreatmentNCT06617832 · Not applicable · University of Aarhus · starts Nov 13, 2024
Phase 3 8
- DihydroergotamineSerotonin 1d (5-HT1d) receptor agonist
- PromethazineHistamine H1 receptor antagonist
- RizatriptanSerotonin 1b (5-HT1b) receptor agonist
- EletriptanSerotonin 1f (5-HT1f) receptor agonist
- SumatriptanSerotonin 1b (5-HT1b) receptor agonist
- TizanidineAdrenergic receptor alpha-2 agonist
- CaffeineAdenosine receptor antagonist
- Anisodine hydrobromide
Phase 2 5
- Tonabersat
- PropranololBeta-1 adrenergic receptor antagonist
- RamelteonMelatonin receptor agonist
- DronabinolCannabinoid CB1 receptor agonist
- CandesartanType-1 angiotensin II receptor antagonist
How its trials ended
94 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 20 whose ending is known, 65% met their primary endpoint, 15% missed it and 20% stopped early.
- Completed, result not reported4144%
- Ongoing2223%
- Met its primary endpoint1314%
- Status unknown1112%
- Missed its primary endpoint33%
- Stopped: enrollment or feasibility33%
- Stopped: other or unclear11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA